Timing of Pegfilgrastim: Association with Febrile Neutropenia in a Pediatric Solid and CNS Tumor Population

Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations

(2017) Matti Aapro et al.   SUPPORTIVE CARE IN CANCER

The effectiveness and safety of same-day versus next-day administration of long-acting granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced neutropenia: a systematic review

(2017) Gary H. Lyman et al.   SUPPORTIVE CARE IN CANCER

Impact of Chemotherapy Dose Intensity on Cancer Patient Outcomes

(2017) Gary H. Lyman   Journal of the National Comprehensive Cancer Network

Trajectory of absolute neutrophil counts in patients treated with pegfilgrastim on the day of chemotherapy versus the day after chemotherapy

(2016) Yanli Li et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

“Same-Day” administration of pegfilgrastim following myelosuppressive chemotherapy: clinical practice and provider rationale

(2016) Sarah Marion et al.   SUPPORTIVE CARE IN CANCER

Burden of Chemotherapy-Induced Febrile Neutropenia Hospitalizations in US Clinical Practice, by Use and Patterns of Prophylaxis with Colony-Stimulating Factor

(2016) Derek Weycker et al.   SUPPORTIVE CARE IN CANCER

Evaluation of the Hematologic Safety of Same Day Versus Standard Administration (24- to 72-Hour Delay) of Pegfilgrastim in Gynecology Oncology Patients Undergoing Cytotoxic Chemotherapy

(2015) Caroline C. Billingsley et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter?

(2015) Derek Weycker et al.   SUPPORTIVE CARE IN CANCER

Core outcomes and definitions for pediatric fever and neutropenia research: A consensus statement from an international panel

(2014) Gabrielle M. Haeusler et al.   PEDIATRIC BLOOD & CANCER

Pharmacokinetics and Pharmacodynamics of Pegfilgrastim

(2011) Bing-Bing Yang et al.   CLINICAL PHARMACOKINETICS

Phase II, Randomized, Open-Label Study of Pegfilgrastim-Supported VDC/IE Chemotherapy in Pediatric Sarcoma Patients

(2010) Sheri L. Spunt et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Trial and Pharmacokinetic Study of Pegfilgrastim versus Filgrastim after Dose-Intensive Chemotherapy in Young Adults and Children with Sarcomas

(2009) E. Fox et al.   CLINICAL CANCER RESEARCH

Pegfilgrastim for prevention of chemotherapy-associated neutropenia in pediatric patients with solid tumors

(2009) Scott C. Borinstein et al.   PEDIATRIC BLOOD & CANCER

The safety and efficacy of day 1 versus day 2 administration of pegfilgrastim in patients receiving myelosuppressive chemotherapy for gynecologic malignancies

(2008) Jenny M. Whitworth et al.   GYNECOLOGIC ONCOLOGY

Risk prediction of fever in neutropenia in children with cancer: A step towards individually tailored supportive therapy?

(2008) Silvia Wicki et al.   PEDIATRIC BLOOD & CANCER